ArticleInfluenza and other respiratory viruses2024
Severe Acute Respiratory Infection (SARI) due to Influenza in Post-COVID Resurgence: Disproportionate Impact on Older Māori and Pacific Peoples.
Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Human Influenza Virus Infection: A Focus on Key Host Determinants Linked to Clinical Disease Severity.Viruses · 2026Review
- Post-COVID-19 Seasonality of Influenza, Respiratory Syncytial Virus, and SARS-CoV-2 Among Hospitalized Children in Western Iran: A Molecular Surveillance Study (2023-2024).Journal of epidemiology and global health · 2025Article
- Risk and resilience factors associated with the progression of influenza to severe disease outcomes: umbrella review protocol.BMJ open · 2025Article
- Estimating excess mortality during the Covid-19 pandemic in Aotearoa New Zealand.International journal of epidemiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveInfluenza reemerged after a 2020-2021 hiatus in 2022, but understanding the resurgence needs pre-COVID era surveillance. We compared age- and ethnicity-specific incidence of severe acute respiratory infection (SARI) from a hospital network in Auckland, New Zealand, in 2022 against a baseline, 2012-2019.
methodsAnnual and monthly influenza SARI incidence per 1000 persons by age and ethnic group between 2012 and 2022 was calculated using resident population as the denominator. The hospitals capture most severe illness of the resident population.
resultsInfluenza SARI incidence was highest among <1 year olds (2.62; 95% CI: 1.84-3.61) during 2012-2019, lowest at 6-14 years, and did not significantly increase until 50-64 years (0.35; 95% CI: 0.27-0.45), reaching 1.19 (95% CI: 0.57-1.55) in those ≥75 years. In all age groups, incidence was at least threefold higher in Māori and Pacific Peoples. No influenza SARI was identified in 2020-2021. In 2022, despite an early peak, annual incidence (<65 years) was lower than baseline in all ethnic groups, but incidence (≥65 years) in Māori (2.06; 95% CI: 1.22-3.26) and Pacific (3.94; 95% CI: 2.97-5.13) peoples was higher in 2022 than most baseline years, whereas incidence in NMNP (0.22; 95% CI: 0.14-0.32) was lower than any baseline year.
conclusionAfter no influenza 2020-2021, Auckland had an early, high, narrow peak in 2022. Stratification by age and ethnicity revealed striking discrepancies in incidence among Māori and Pacific adults over 65 years compared with NMNP adults, with implications for targeted vaccination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.